Ofloxacin - Pharma Manufacturer

More documents

Recommendations

Info

Acute,UncomplicatedUrethral and CervicalGonorrhea400mgsingledose1 day 400 mgNongonococcalCervicitis/Urethritisdue to C.trachomatisMixed Infection ofthe urethra andcervix due to C.trachomatis and N.gonorrhoeae300mg300mgq12h 7 days 600 mgq12h 7 days 600 mgAcuteInflammatoryDiseasePelvic400mgq12h10-14days800 mgUncomplicatedCystitis due to E. colior K. pneumoniaeUncomplicatedCystitis due to otherapproved pathogens200mg200mgq12h 3 days 400 mgq12h 7 days 400 mgComplicated UTI's200mgq12h 10 days 400 mgProstatitis due toE.Coli300mgq12h6 weeks 600 mgPatients with Impaired Renal Function: Dosage should be adjusted forpatients with a creatinine clearance < 50 mL/min. After a normal initial dose,dosage should be adjusted as follows:Creatinine ClearanceMaintenanceDoseFrequency20-50 mL/minthe usualrecommended q24hunit dose
20 mL/min½ the usualrecommendedunit doseq24hPatients with Cirrhosis: The excretion of ofloxacin may be reduced in patientswith severe liver function disorders (e.g., cirrhosis with or without ascites). Amaximum dose of 400 mg of ofloxacin per day should therefore not be exceeded.Side effects: The most frequent side effects include nausea, vomiting, diarrhea,insomnia, headache, dizziness, itching, and vaginitis in women. Rare allergicreactions have been described, such as hives and anaphylaxis (shock).Symptoms of nervous system stimulation, such as anxiety, euphoria, andhallucinations have rarely been reported.Precautions:General: Periodic assessment of organ system functions, including renal,hepatic and hematopoietic, is advisable during prolonged therapy. Adequatehydration of patients receiving ofloxacin should be maintained to prevent theformation of highly concentrated urine.Renal/Hepatic: Administer ofloxacin with caution in the presence of renal orhepatic insufficiency/impairment. In patients with known or suspected renal orhepatic insufficiency/impairment, careful clinical observation and appropriatelaboratory studies should be performed prior to and during therapy sinceelimination of ofloxacin may be reduced. Alteration of the dosage regimen isnecessary for patients with impairment of renal function (creatinine clearance £50mL/min).Allergic Reactions: Moderate to severe phototoxicity reactions have beenobserved in patients who are exposed to direct sunlight while receiving somedrugs in this class including ofloxacin. Excessive sunlight should be avoided.Therapy should be discontinued if phototoxicity (e.g., a skin eruption, etc.)occurs.Pregnancy: Safety and efficacy have not been established in pregnant women.<strong>Ofloxacin</strong> should not be used during pregnancy unless the potential benefitjustifies the potential risk to the fetus.Children: Safety and effectiveness in children and adolescents below the age of18 years have not been established. <strong>Ofloxacin</strong> causes arthropathy (arthrosis)and osteochondrosis in juvenile animals of several species.Patients with Special Diseases and Conditions:CNS Disorders: As with all quinolones, ofloxacin should be used with caution inany patient with a known or suspected CNS disorder that may predispose toseizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis,epilepsy, etc.) or in the presence of other risk factors that may predispose toseizures or lower the seizure threshold (e.g., certain drug therapy, renal
Page 1: OfloxacinIntroduction: Ofloxacin is

Ofloxacin - Pharma Manufacturer

Create successful ePaper yourself

Delete template?

Save as template?